Does Wegovy stop food noise the way Mounjaro does?

What do people actually mean by "food noise", and can either medicine switch it off?

"Food noise" is the everyday word for that near-constant mental hum about eating: planning the next meal, snacking without hunger, circling back to the biscuit tin long after dinner. It isn't a medical diagnosis, so you won't find it in a leaflet. But it maps closely onto appetite regulation, which is exactly where these medicines act.

Both Wegovy and Mounjaro slow gastric emptying, so food stays in your stomach longer and physical fullness lasts. Both also act on GLP-1 receptors involved in appetite signalling, dialling down the drive to eat. That combination is why so many people report the mental chatter softening rather than switching off with a click. It usually eases in, not overnight.

The honest answer is that neither medicine is guaranteed to silence food noise, and the effect varies from person to person. Some people notice a marked change within the first couple of weeks; others feel it more gradually as their dose is adjusted upward by a prescriber. The NHS describes reduced appetite and feeling fuller as expected effects of both tirzepatide and semaglutide, alongside the more familiar physical changes.

What matters for this comparison is that the appetite effect isn't a bonus side effect. It's central to how both medicines help with weight, prescribed alongside a reduced-calorie diet and more activity. If food noise is your main frustration, that's a genuinely reasonable thing to raise at a consultation, and it's one of the questions our prescribers hear most weeks.

• Learn more on our Wegovy versus Mounjaro comparison.

How does the one-pathway versus two-pathway difference change the effect?

This is the mechanical heart of the comparison. Wegovy is a brand of semaglutide, made by Novo Nordisk, and it's a GLP-1 receptor agonist. That means it works on a single gut-hormone pathway. Mounjaro is a brand of tirzepatide, made by Eli Lilly, and it's a dual agonist: it activates both the GLP-1 and the GIP receptors. It's the only dual-agonist weight-management medicine licensed in the UK.

In practical terms, both pathways are involved in appetite and blood-sugar regulation. GLP-1 slows stomach emptying and signals fullness. Adding GIP appears to enhance those effects for many people, which is the theory behind tirzepatide's generally larger average results in trials. Whether that translates into a quieter head for you specifically is harder to predict, because appetite response is personal.

It helps to remember that "more pathways" doesn't automatically mean "better for everyone". Some people respond very well to semaglutide and never need to consider anything else. Others find the dual mechanism suits them better. Tolerance, existing health conditions and how your body handles the medicine all feed into the picture, which is why this is a clinical conversation rather than a simple ranking.

Both start low and build slowly. Wegovy begins at 0.25mg; Mounjaro begins at 2.5mg. Those first doses exist to let your system settle rather than to deliver the full appetite effect, so early food-noise changes may be modest and build as the prescriber titrates you upward. You can compare the two mechanisms in more depth on our tirzepatide and semaglutide overview.

What does the trial evidence say about how much each one does?

Trial data is where this comparison gets its clearest signal, though it measures weight change rather than food noise directly. In the SURMOUNT-1 trial, tirzepatide produced average body-weight reductions of roughly 20 to 21 percent at the 15mg dose over 72 weeks. Semaglutide 2.4mg, in the STEP 1 trial, produced around 15 percent over 68 weeks. Both figures are averages across thousands of adults, not promises for any individual.

The most direct evidence comes from SURMOUNT-5, an open-label head-to-head trial of 751 adults with obesity and no diabetes, run over 72 weeks and published in NEJM in 2025. It found tirzepatide produced greater average weight reduction than semaglutide 2.4mg. That's the strongest single comparison available, and NICE's appraisal of tirzepatide has noted that indirect comparisons also tend to favour it.

The gap narrows at the top end. The MHRA approved a higher Wegovy 7.2mg dose, with trial results reporting around 20.7 percent average weight loss over 72 weeks, approaching tirzepatide 15mg territory. You can read the details in the NICE appraisal of tirzepatide (TA1026) and the SURMOUNT-1 trial paper. Trial averages tell you about typical response, not about your head at breakfast.

Do both feel the same day to day, or does the routine differ?

The rhythm of using them is very similar. Both are once-weekly subcutaneous injections you can give yourself in the abdomen, thigh or upper arm, rotating the site each time. You pick a day, and most people build the injection into a fixed weekly moment so it's hard to forget. That regularity matters more than which day you choose.

Storage is where a small practical difference shows. Both come as pre-filled pens that live in the fridge, typically tucked in the door next to the everyday things you reach for, and both have a limited room-temperature window once in use. We won't quote a specific number of days here because the exact window differs by product and can change; the patient leaflet and SmPC are the place to check, and our aftercare team will point you to the right figure for your pen.

The appetite experience day to day tends to feel comparable in kind even if it differs in degree. Many people describe smaller portions filling them, less interest in snacking, and that quieter mental hum. Some notice they simply forget to think about food between meals in a way that felt impossible before. Others find the effect is stronger in the days just after each dose.

Neither medicine is a set-and-forget arrangement. Both are prescribed alongside dietary change and more movement, and both work best when you keep protein, hydration and some strength activity in the picture as your appetite falls. Our page on weight-loss treatment options sets out how that wider picture fits together, whichever medicine you end up on.

Are the side effects different between them?

The side-effect profiles overlap heavily, because both are gut-hormone medicines. The most common effects are digestive: feeling sick, being sick, loose stools or constipation, indigestion, burping, and sometimes tiredness, headache or dizziness. These are usually most noticeable soon after starting or after a dose increase, and for many people they settle within days to a couple of weeks. Both carry the MHRA's Black Triangle for extra monitoring.

Because tirzepatide's average effect tends to be larger, some people find its early side effects feel more pronounced, though this varies widely and isn't a rule. The gradual dose build on both medicines is designed partly to keep these effects manageable, which is another reason the starting doses are deliberately low.

There are less common but more serious risks to be aware of on both. In January 2026 the MHRA issued a safety update flagging acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 medicines: severe, persistent stomach pain that may spread to your back, with or without vomiting, needs urgent medical help. Gallbladder problems and dehydration from severe sickness are also worth knowing about. If anything feels wrong, you can reach our aftercare team seven days a week, or contact us through our support page.

You can report any suspected side effect through the MHRA Yellow Card scheme, and the NHS semaglutide page lists the common effects in plain terms. A prescriber will go through your history to check either medicine is appropriate before you start, and will review you before any repeat.

Which one is right if food noise is my main problem?

If food noise is the thing driving you, both medicines are reasonable candidates, because appetite regulation is central to how each works rather than incidental. There isn't a test that predicts which will quieten your head more, so the choice leans on your fuller health picture: your BMI and any weight-related conditions, your medical history, other medicines you take, and how your body tolerates the treatment once you begin.

Some people start on one medicine and find it does the job well. Others adjust over time under clinical guidance. A larger average trial effect for tirzepatide doesn't mean it's automatically the better fit for you, and a smaller average doesn't mean semaglutide won't quiet food noise effectively in your case. Individual response genuinely varies.

Both are licensed for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, high cholesterol, prediabetes or sleep apnoea. Lower thresholds can apply for some ethnic backgrounds under UK guidance. Neither is recommended in pregnancy, when breastfeeding or when trying to conceive, and neither is licensed for under-18s.

This is exactly the kind of nuance a clinical assessment is built for. At nume, a named prescriber reads your answers, not a piece of software, and can talk through which mechanism might suit your situation. You can meet the clinical team behind that on our clinical lead's profile. Start your free consultation if you'd like that conversation.

How do I get either medicine safely, and can I trust an online pharmacy?

Both Wegovy and Mounjaro are prescription-only medicines, so the only legal UK route is a prescription following a proper clinical assessment. That's true whether you go through the NHS, a GP or a regulated online pharmacy. NHS access is phased and tightly criteria-based, with long waits common, which is why many people look at a private route instead.

Safety online comes down to verification. You can check any UK online pharmacy on the General Pharmaceutical Council register before you buy anything; nume's pharmacy is GPhC-registered and verifiable there. Treat certain things as red flags: sellers offering these injections without a clinical assessment, social-media sellers, prices far below the market, and "discount codes" from unknown sources. The MHRA has warned repeatedly about fake weight-loss pens, and large seizures of counterfeit product have been made.

With nume, the consultation is free and read the same day by a GPhC-registered Independent Prescriber. If treatment is clinically suitable and you order before 12pm on a weekday, it's dispatched the same day and delivered free the next working day by DPD, in plain packaging. There's no subscription; every repeat is clinically re-reviewed. You can read more about how we work on our about page.

Which suits you is a clinical decision our prescribers make with you, taking in your health, your history and your goals rather than a trial average.

Related questions we've answered

• Wegovy versus Mounjaro: the full comparison
• Tirzepatide versus semaglutide on cost
• Weight-loss treatment options at nume
• Common questions about our service